Vivos Therapeutics Analyst Ratings
BenzingaAug 20 05:33 ET
Ascendiant Remains a Buy on Vivos Therapeutics (VVOS)
TipRanksApr 12, 2023 03:10 ET
Benzinga Analyst RatingsJan 17, 2023 05:38 ET
Ascendiant Capital Initiates Coverage On Vivos Therapeutics With Buy Rating, Announces Price Target of $2.5
Benzinga Real-time NewsJan 17, 2023 05:38 ET
No Data